AI giants and DNA control

The development of artificial intelligence is increasingly raising not only investor enthusiasm and excitement among technology companies, but also serious security concerns. This time, the biggest players in the AI industry have come forward with an unusual initiative: the leaders of OpenAI, Anthropic, Google DeepMind, and Microsoft AI have called on governments to tighten control over DNA and RNA synthesis, fearing that modern neural networks could significantly simplify the creation of dangerous biological agents.

According to WIRED, the open letter was signed by OpenAI CEO Sam Altman, Anthropic CEO Dario Amodei, Google DeepMind founder Demis Hassabis, and Microsoft AI head Mustafa Suleyman. The initiative was also supported by scientists, biosecurity experts, national security specialists, and representatives of companies in the gene synthesis industry. The authors propose enshrining mandatory customer and order screening for all providers of synthetic nucleic acids in legislation. In their view, every order for the production of artificial DNA or RNA fragments should undergo thorough analysis, and the identity of the customer must be verified before work begins.

In addition, the initiative calls for detailed record-keeping of such operations and stricter control over specialized equipment used for genetic material synthesis.

At first glance, such measures may seem excessive. However, experts point to a fundamentally new problem that has emerged with the rise of modern language models. Previously, creating complex biological constructs required years of education, specialized knowledge, and access to scientific literature. Today, artificial intelligence can significantly lower this barrier.

The authors of the letter warn that modern neural networks are already capable of analyzing vast amounts of scientific publications, identifying patterns, and assisting in solving complex research problems. In the future, these capabilities could be used not only in medicine and biotechnology, but also for potentially dangerous purposes.

In effect, AI can accelerate the development of new drugs, vaccines, and treatments, but at the same time it could theoretically help malicious actors design toxic substances, modify existing pathogens, or find ways to bypass biological constraints.

For this reason, the authors of the initiative describe order screening as one of the most effective and least burdensome protective measures. Instead of restricting scientific research, they propose controlling access to the most sensitive technologies and flagging suspicious requests at the ordering stage.

The issue is becoming even more relevant amid the rapid growth of synthetic biology. Today, scientists are already capable of creating segments of genomes synthetically, and the cost of such procedures has significantly decreased in recent years. What once required the resources of a major research center is gradually becoming accessible to a much broader range of organizations.

At the same time, the industry already has certain self-regulatory mechanisms in place. Some major companies, including Twist Bioscience, voluntarily screen customers and analyze genetic sequences ordered by clients. These measures help identify attempts to synthesize dangerous viruses or toxins before production begins.

However, the problem lies in the lack of unified mandatory rules. Currently, some companies follow high safety standards voluntarily, while others operate under less strict procedures. As a result, there is a risk of “weak links” in the control system.

Against this backdrop, a bipartisan bill has already been introduced in the U.S. Senate that would require mandatory screening of all gene synthesis service customers. The bill includes analysis of potential links between clients and terrorist organizations, as well as detection of attempts to create dangerous pathogens or reconstruct known viruses that pose a threat to public health.

Interestingly, the debate is unfolding alongside unprecedented growth in biotechnology investment. In June 2025, the major medical charity Wellcome Trust allocated £10 million to launch the world’s first project aimed at creating parts and potentially even entire human genomes from scratch. Many scientists view such research as the next stage in the development of medicine and bioengineering.

The potential benefits of these technologies are enormous. In the future, synthetic biology could enable new treatments for genetic diseases, the growth of artificial tissues and organs, cancer therapies, more effective vaccines, and even the restoration of extinct species.

However, risks are growing alongside the opportunities. As gene-editing tools become more accessible, oversight of their use becomes increasingly important. That is why the largest companies, which are themselves at the forefront of the technological revolution, are increasingly advocating for new safety rules.

The situation is highly symbolic. Just a few years ago, the main debate around AI focused on job losses and human-machine competition. Today, industry leaders are discussing far more serious issues – how to prevent AI from being used to create biological threats.

In essence, the world now stands at the intersection of two transformative technologies – artificial intelligence and synthetic biology. Each alone has the potential to radically reshape medicine and science. But their combination creates such powerful capabilities that safety considerations are moving to the forefront.

Therefore, this initiative by AI giants may represent only the first step toward a new global biosecurity framework, where control over DNA synthesis becomes as critical to protection as nuclear oversight or cybersecurity today.